TY - JOUR
T1 - In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae
AU - Clark, Justin A.
AU - Kulengowski, Brandon
AU - Burgess, David S.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints.
AB - We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints.
KW - Aminoglycoside resistance
KW - Carbapenem-resistant Enterobacteriaceae
KW - Plazomicin
KW - Susceptibility testing
UR - http://www.scopus.com/inward/record.url?scp=85089010608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089010608&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2020.115117
DO - 10.1016/j.diagmicrobio.2020.115117
M3 - Article
C2 - 32755805
AN - SCOPUS:85089010608
SN - 0732-8893
VL - 98
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
M1 - 115117
ER -
